Moving into the mainstream: Healthcare professionals’ views of implementing treatment focussed genetic testing in breast cancer care

N Hallowell, Sarah Wright, Diane Stirling, Charles Gourley, Oliver Young, Mary Porteous

Research output: Contribution to journalArticlepeer-review

Abstract

A proportion of breast cancers are attributable to BRCA1 or BRCA2 mutations. Technological advances has meant that mutation testing in newly diagnosed cancer patients can be used to inform treatment plans. Although oncologists increasingly deliver treatment-focused genetic testing (TFGT) as part of mainstream ovarian cancer care, we know little about non-genetics specialists’ views about offering genetic testing to newly diagnosed breast cancer patients. This study sought to determine genetics and non-genetics specialists’ views of a proposal to mainstream BRCA1 and 2 testing in newly diagnosed breast cancer patients. Qualitative interview study. Nineteen healthcare professionals currently responsible for offering TFGT in a standard (triage + referral) pathway (breast surgeons + clinical genetics team) and oncologists preparing to offer TFGT
to breast cancer patients in a mainstreamed pathway participated in in-depth interviews. Genetics and non-genetics professionals’ perceptions of mainstreaming are influenced by their views of: their clinical roles and responsibilities, the impact of TFGT on their workload and the patient pathway and the perceived relevance of genetic testing for patient care in the short-term. Perceived barriers to mainstreaming may be overcome by: more effective communication between specialities, clearer guidelines/patient pathways and the recruitment of mainstreaming champions.
Original languageEnglish
Pages (from-to)293-301
Number of pages9
JournalFamilial Cancer
Volume18
Issue number3
Early online date28 Jan 2019
DOIs
Publication statusPublished - 14 Jun 2019

Fingerprint Dive into the research topics of 'Moving into the mainstream: Healthcare professionals’ views of implementing treatment focussed genetic testing in breast cancer care'. Together they form a unique fingerprint.

Cite this